COMPOSITIONS AND METHODS FOR PROMOTING TISSUE REPAIR AND WOUND HEALING

• US 20090318355A1
• Filed: 05/13/2009
• Published: 12/24/2009
• Est. Priority Date: 02/15/2006
• Status: Abandoned Application

• Current Assignee: EP Therapeutics, Inc.
• Original Assignee: EP Therapeutics, Inc.
• Inventors: Chen, Thomas T., Chen, Maria J.M.
• Application Number:
  US12/465,065
• Publication Number:
  US 20090318355A1
• Time in Patent Office: Days
• US Class Current: 514/1.100
• CPC Class Codes: A61K 38/30 Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2 insulin-like growth factor binding protein A61K38/1754
• CPC Class Codes: A61K 8/64 Proteins; Peptides; Derivatives or degradation products thereof
• CPC Class Codes: A61P 17/02 for treating wounds, ulcers, burns, scars, keloids, or the like
• CPC Class Codes: A61Q 19/08 Anti-ageing preparations

Abstract

A method is described for using the Ea4-peptide of pro-IGF-I or human Eb-peptide of pro-IGF-I for enhancing the proliferation of fibroblasts and closure of wound. The peptide species can be homologous of trout Ea4-peptide, human Eb-peptide of pro-IGF-I or a fusion protein comprising the Ea4- or Eb-peptide of pro-IGF-I. It can be administered any wound in a pharmaceutically acceptable composition alone or in combination with other compounds.

Claims

1. A method for the promotion of wound repair comprising administering to a wound site an effective amount of a composition comprising an Insulin-like Growth Factor-1 (IGF-1) E-domain peptide (E-peptide) together with at least one of a pharmaceutically acceptable carrier, excipient or adjuvant, wherein the composition promotes repair of the wound.

2. The method of claim 1, wherein the composition comprises at least one E-domain peptide having the amino acid sequence as set forth in SEQ ID NO:

2, having the amino acid sequence as set forth in SEQ ID NO;

1, or a combination of both.

3. The method of claim 2, wherein the composition comprises a fusion protein having an E-domain peptide joined in a contiguous polypeptide chain with a non-E-domain peptide.

4. The method of claim 1, wherein the wound is at least one of a burn, cut, abrasion, lesion, sore, infection, irritation, inflammation, fibrosis or necrosis.

5. The method of claim 1, wherein the composition is in a pharmaceutical form adapted for topical administration.

6. The method of claim 5, wherein the pharmaceutical form is at least one member selected from the group consisting of gel, lotion, emulsion, liquid, nebulized spray, foam, and combination thereof.

8. The method of claim 3, wherein the non-E-domain peptide comprises a fluorescent protein.

9. The method of claim 3, wherein the non-E-domain peptide comprises a TAT polypeptide or portion thereof.

10. The method of claim 1, wherein the tissue damage is due to a surgical procedure or device.

11. The methods of claim 1, wherein the composition comprises a cosmetically suitable carrier.

7. A method for promoting fibroblast proliferation comprising administering a composition comprising an effective amount of an E-domain peptide selected from the group consisting of an Ea4-domain peptide having the amino acid sequence of SEQ ID NO:

2, an hEb domain having the amino acid sequence of SEQ ID NO;

1, and a combination thereof, together with at least one of a pharmaceutically acceptable carrier, excipient or adjuvant.

12. A surgical adjuvant for the amelioration of tissue damage due to a surgical procedure, surgical device or surgical implant comprising an effective amount of an E-domain peptide together with at least one of a pharmaceutically acceptable carrier, excipient or adjuvant.